Costs lowest when bDMARD sequences start with etanercept biosimilar
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2020 Category: Drugs & Pharmacology Source Type: news

Pharmacy benefits manager Abarca inks discount deal for Amgen's Enbrel
Abarca, a small Puerto Rico-based pharmacy benefits manager, said on Tuesday Amgen Inc had agreed to give its health insurer clients an additional discount on its blockbuster rheumatoid arthritis drug Enbrel, if patients discontinue taking it after three months. (Source: Reuters: Health)
Source: Reuters: Health - December 3, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

iRhom2 inhibits bile duct obstruction-induced liver fibrosis
Chronic liver disease can induce prolonged activation of hepatic stellate cells, which may result in liver fibrosis. Inactive rhomboid protein 2 (iRhom2) is required for the maturation of A disintegrin and metalloprotease 17 (ADAM17, also called TACE), which is responsible for the cleavage of membrane-bound tumor necrosis factor–α (TNF-α) and its receptors (TNFRs). Here, using the murine bile duct ligation (BDL) model, we showed that the abundance of iRhom2 and activation of ADAM17 increased during liver fibrosis. Consistent with this, concentrations of ADAM17 substrates were increased in plasma samples f...
Source: Signal Transduction Knowledge Environment - October 29, 2019 Category: Science Authors: Sundaram, B., Behnke, K., Belancic, A., Al-Salihi, M. A., Thabet, Y., Polz, R., Pellegrino, R., Zhuang, Y., Shinde, P. V., Xu, H. C., Vasilevska, J., Longerich, T., Herebian, D., Mayatepek, E., Bock, H. H., May, P., Kordes, C., Aghaeepour, N., Mak, T. W., Tags: STKE Research Articles Source Type: news

Amgen Wins U.S. Patent Battle on Arthritis Drug Enbrel, Thwarting Novartis Amgen Wins U.S. Patent Battle on Arthritis Drug Enbrel, Thwarting Novartis
A U.S. judge on Friday said two patents relating to Amgen Inc's blockbuster rheumatoid arthritis drug Enbrel (etanercept) were valid, denying a challenge by Novartis AG, which is seeking to launch a copycat version.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - August 13, 2019 Category: Orthopaedics Tags: Rheumatology News Source Type: news

Amgen wins Enbrel patent protections — for now
Amgen has fought off a patent challenge from Novartis to its blockbuster anti-inflammatory, Enbrel. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 12, 2019 Category: Pharmaceuticals Source Type: news

Amgen wins U.S. patent battle on arthritis drug Enbrel, thwarting Novartis
A U.S. judge on Friday said two patents relating to Amgen Inc's blockbuster rheumatoid arthritis drug Enbrel were valid, denying a challenge by Novartis AG, which is seeking to launch a copycat version. (Source: Reuters: Health)
Source: Reuters: Health - August 9, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Etanercept Tx for Autoimmune Disease May Up Risk for IBD
MONDAY, July 15, 2019 -- Patients with autoimmune diseases have an increased risk for being diagnosed with Crohn disease (CD) or ulcerative colitis (UC) while under treatment with etanercept, according to a study published online July 2 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 15, 2019 Category: Pharmaceuticals Source Type: news

etanercept (Enbrel)
Title: etanercept (Enbrel)Category: MedicationsCreated: 3/2/1999 12:00:00 AMLast Editorial Review: 6/28/2019 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - June 28, 2019 Category: Dermatology Source Type: news

Infection Risk Lower With Certain Psoriasis Treatments
MONDAY, May 13, 2019 -- For patients with psoriasis treated with systemic medications, the risk for serious infection is reduced for new users of apremilast, etanercept, and ustekinumab versus methotrexate, according to a study published online May... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 13, 2019 Category: Pharmaceuticals Source Type: news

Eticovo (Etanercept Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 2, 2019 Category: Drugs & Pharmacology Source Type: news

Eticovo (Etanercept Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 1, 2019 Category: Drugs & Pharmacology Source Type: news

FDA OKs Second Etanercept Biosimilar for Inflammatory Diseases FDA OKs Second Etanercept Biosimilar for Inflammatory Diseases
Etanercept-ykro (Eticovo) is approved across all eligible indications for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis.FDA Approvals (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - April 30, 2019 Category: Rheumatology Tags: Rheumatology News Alert Source Type: news

FDA Approves Eticovo (etanercept-ykro), a Biosimilar to Enbrel (etanercept)
April 26, 2019 The FDA has approved Eticovo (etanercept-ykro), a biosimilar to U.S.-licensed Enbrel (etanercept). A biosimilar product is a biological product that is approved based on a showing that it is highly similar to an already-FDA approved... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 27, 2019 Category: Drugs & Pharmacology Source Type: news

FDA Approves Eticovo (etanercept-ykro), a Biosimilar to Enbrel
INCHEON, Korea– As of April 2019– Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved Eticovo (etanercept-ykro), a biosimilar referencing Enbrel (etanercept), across all eligible... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 27, 2019 Category: Drugs & Pharmacology Source Type: news

Drug Survival Rates Highest for Ustekinumab for Pediatric Psoriasis
THURSDAY, March 28, 2019 -- In real-life conditions, drug survival rates are higher for ustekinumab than for adalimumab and etanercept for all treatments and types of psoriasis in children, according to a study published online March 18 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 28, 2019 Category: Pharmaceuticals Source Type: news

High drug prices? Some pharma firms will send you a check
Kip Burgess was relieved last year when pharmaceutical giant Amgen overnighted him a $2,976 check to help pay for his go-to arthritis drug, Enbrel. (Source: CNN.com - Health)
Source: CNN.com - Health - December 28, 2018 Category: Consumer Health News Source Type: news

The Little-Known Way Pharma Companies Hook People On Their Costly Drugs
Kip Burgess was relieved last year when pharmaceutical giant Amgen overnighted him a $2,976 check to help pay for his go-to arthritis drug, Enbrel. The 36-year-old psychologist had run into an increasingly common problem: The copay coupon sent by Amgen couldn’t cover the drug’s more than $4,000 monthly price. “Nothing in the world gives me more anxiety than just getting my medication,” Burgess said. “There’s nothing you can do but beg.” Panicked, Burgess had called Amgen and pleaded for help. The drugmaker sent him the check after he provided a credit card statement and an explanat...
Source: TIME: Health - December 12, 2018 Category: Consumer Health News Authors: Sarah Jane Tribble / Kaiser Health News Tags: Uncategorized Drugs Source Type: news

Questions Remain About Etanercept to Biosimilar Switch Questions Remain About Etanercept to Biosimilar Switch
Nationwide registry data from patients with inflammatory arthritis showed many had similar outcomes with biosimilar, but the study did not show conclusively that the two drugs are interchangeable.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 21, 2018 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Medical News Today: Differences between Enbrel and Humira
Enbrel and Humira are medications that doctors prescribe to treat rheumatoid arthritis and other conditions. Both help lower inflammation in the joints and are similar, regarding their available forms, storage, and costs. Learn more about Enbrel and Humira, and which might be the most appropriate, here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 13, 2018 Category: Consumer Health News Tags: Rheumatoid Arthritis Source Type: news

First Head-to-Head Trial of a TNF Inhibitor Versus Methotrexate Monotherapy in Psoriatic Arthritis Shows ENBREL ® (Etanercept) Monotherapy and Combination Therapy Both Superior to Methotrexate
Results From Head-To-Head Phase 3 SEAM-PsA Study Assessing ENBREL and Methotrexate Regimens in Patients With Psoriatic Arthritis Presented at 2018 ACR/ARHP Annual Meeting Additional Phase 3b Results Show Modified ENBREL Formulation Associated With Significantly Lower Mean Injection Site Pain Versus Prior Formulation Data Presentations Result of Continued Dedication to Evaluate Optimal Use of ENBREL THOUSAND OAKS, Calif., Oct. 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that positive results from the Phase 3 SEAM-PsA study comparing the efficacy of Enbrel® (etanercept) monotherapy and ENBREL pl...
Source: Amgen News Release - October 24, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Bringing Hollywood to Medtech
Typically, the tutorials for medical devices aren’t extremely flashy. The videos convey a simple message and get straight to the point. However, one company is bringing high quality production levels to the medtech industry. Spotburner is a specialist in producing videos for healthcare companies. “I have a television studio and I have been producing commercials for about 20 years,” Bob Bekian, CEO of Spotburner told MD+DI. “Typically, these sort of productions (medical device videos) have been a must-do, but they haven’t been able to ...
Source: MDDI - July 27, 2018 Category: Medical Devices Authors: Omar Ford Tags: Regulatory and Compliance Source Type: news

Biocon puts arthritis drug on backburner
Biocon and Mylan have been working for a decade on a biosimilar version of the drug, originally sold by Amgen under brand name Enbrel. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 11, 2018 Category: Pharmaceuticals Source Type: news

Lupin and Mylan Partner to Commercialize Enbrel(R) (Etanercept) Biosimilar
MUMBAI, India and HERTFORDSHIRE, England and PITTSBURGH, June 28, 2018 -- (Healthcare Sales & Marketing Network) -- Pharma major Lupin Limited (Lupin) and global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that the two companies will p... Biopharmaceuticals, Generics Mylan, Lupin, biosimilar, Enbrel, etanercept (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 28, 2018 Category: Pharmaceuticals Source Type: news

Lupin-Mylan team up for biosimilar Etanercept
Under the terms of the agreement, Lupin will receive an up-front payment of $15 million and potential commercial milestones together with an equal share in net profits of the product. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 28, 2018 Category: Pharmaceuticals Source Type: news

Lupin, Nichi-Iko tie up for commercialization of biosimilar Etanercept in Japan
Mumbai based Lupin pharma and Japan's Nichi-Iko have tied up for the distribution, promotion and sale of Lupin ’s recently-filed biosimilar Etanercept in Japan. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 18, 2018 Category: Pharmaceuticals Source Type: news

Novartis touts effectiveness, safety of autoimmune drug copies
ZURICH (Reuters) - Novartis on Friday touted safety and efficacy of its biosimilar copies of Johnson& Johnson's Remicade and Amgen Inc's Enbrel, citing a study it hopes will help convince doctors that switching from the original medicines is a viable alternative for treating autoimmune diseases. (Source: Reuters: Health)
Source: Reuters: Health - June 15, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Psoriasis Drugs Strike Immune Targets (Raptiva, Enbrel)
Title: Psoriasis Drugs Strike Immune Targets (Raptiva, Enbrel)Category: Doctor's& Expert's views on SymptomsCreated: 11/20/2003 12:00:00 AMLast Editorial Review: 6/13/2018 2:55:08 PM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - June 13, 2018 Category: Dermatology Source Type: news

Low Doses of Etanercept to Maintain Remission in PsA Low Doses of Etanercept to Maintain Remission in PsA
Find out how psoriatic arthritis patients who have achieved sustained remission with etanercept may benefit from a dosing interval increase.Journal of Clinical Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 23, 2018 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Finding Good Candidates for Risk-Sharing Arrangements
Continued from Part I that discusses the tools device manufacturers can use to manage risk How to find good candidates? Not all devices are created equal. But how can device manufacturers identify the low-hanging fruit for a risk-sharing arrangement? Needless to say, the more characteristics a product has that are associated with successful risk-sharing arrangements, the more such an arrangement is likely to succeed. To illustrate, in Exhibit 1, we chart a select number of risk-sharing arrangements established since 2015 along two key dimensions: product effectiveness and time needed to observe expected outcomes. The findi...
Source: MDDI - April 3, 2018 Category: Medical Devices Authors: Harry Liu and Christine Chen Tags: Contract Manufacturing Design Source Type: news

Etanercept Biosimilar Is Effective, Well-tolerated for Rheumatoid Arthritis Etanercept Biosimilar Is Effective, Well-tolerated for Rheumatoid Arthritis
The biosimilar LBEC0101 is equivalent to etanercept (Enbrel) in treating patients with rheumatoid arthritis (RA) who respond inadequately to methotrexate, according to researchers from Korea and Japan.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - February 20, 2018 Category: Orthopaedics Tags: Rheumatology News Source Type: news

Factors ID'd That Predict RA Remission with Etanercept (CME/CE)
(MedPage Today) -- Leaner patients with less active disease most likely to show strong response (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 21, 2018 Category: Primary Care Source Type: news

Biological Therapies and Improvements in QoL in Psoriasis Biological Therapies and Improvements in QoL in Psoriasis
This study compared the effectiveness of adalimumab, etanercept and ustekinumab on improvements in HRQoL in patients with psoriasis. What factors are associated with these improvements?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 16, 2018 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Etanercept, Tocilizumab and Interleukin-1 Inhibitors in JIA Etanercept, Tocilizumab and Interleukin-1 Inhibitors in JIA
What do we currently know about the efficacy and safety of these biologic agents in the treatment of systemic onset juvenile idiopathic arthritis?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 16, 2018 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Arthritis Drugs Show How US Drug Prices Defy Economics Arthritis Drugs Show How US Drug Prices Defy Economics
Wholesale prices for Humira and Enbrel, the two most commonly used treatments for rheumatoid arthritis, known as RA, increased more than 70 percent in the past three years.Kaiser Health News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 28, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news

A repurposed drug could open door to more stem cell transplants
(University of British Columbia) Etanercept, a drug used to treat arthritis and psoriasis, boosted the survival of blood stem cells in a mouse model. The findings provide a strong basis for a clinical trial to see whether etanercept or a similar drug would improve outcomes for people receiving blood stem cell transplants. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 20, 2017 Category: Cancer & Oncology Source Type: news

Erelzi (etanercept-szzs Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 19, 2017 Category: Drugs & Pharmacology Source Type: news

Amgen launches Enbrel Mini single-dose cartridges with reusable auto-injector
Amgen (NSDQ:AMGN) announced today the U.S. launch of its Enbrel Mini single-dose prefilled cartridges delivered using its reusable AutoTouch auto-injector. The drug-device combination was designed with a needle that stays hidden during injection and a sensor to detect placement on the skin. Get the full story at our sister site, Drug Delivery Business News. The post Amgen launches Enbrel Mini single-dose cartridges with reusable auto-injector appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 17, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Orthopedics Pharmaceuticals Wall Street Beat Amgen Source Type: news

Amgen Launches The ENBREL Mini(TM) Single-Dose Prefilled Cartridge With AutoTouch(TM) Reusable Autoinjector That Is Ergonomically Designed For Patients
Innovative Reusable Autoinjector Provides Additional Administration Option for Enbrel® (Etanercept) Users Awarded Arthritis Foundation Ease of Use (SM) Commendation THOUSAND OAKS, Calif., Nov. 17, 2017 -- (Healthcare Sales & Marketing Network) -... Biopharmaceuticals, Devices, Drug Delivery, Product Launch Amgen, ENBREL Mini, Enbrel, Etanercept, autoinjector (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 17, 2017 Category: Pharmaceuticals Source Type: news

Amgen Launches The ENBREL Mini ™ Single-Dose Prefilled Cartridge With AutoTouch™ Reusable Autoinjector That Is Ergonomically Designed For Patients
Innovative Reusable Autoinjector Provides Additional Administration Option for Enbrel® (Etanercept) Users Awarded Arthritis Foundation Ease of Use (SM) Commendation THOUSAND OAKS, Calif., Nov. 17, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced that the ENBREL Mini™ with AutoTouch™ is now available in the United States (U.S.). Awarded the Arthritis Foundation Ease of UseSM Commendation, this new and innovative delivery system provides an additional administration option for appropriate ENBREL patients. The AutoTouch™ reusable autoinjector has an ergonomic design that includes feature...
Source: Amgen News Release - November 17, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Patients' drugs fail to arrive  at their homes
The 42-year-old teacher has ankylosing spondylitis — a type of inflammatory arthritis which mainly affects the spine — and has been treating it with injections of etanercept since 2009. (Source: the Mail online | Health)
Source: the Mail online | Health - November 14, 2017 Category: Consumer Health News Source Type: news

The patients left in despair as drugs fail to arrive  
The 42-year-old teacher has ankylosing spondylitis — a type of inflammatory arthritis which mainly affects the spine — and has been treating it with injections of etanercept since 2009. (Source: the Mail online | Health)
Source: the Mail online | Health - November 14, 2017 Category: Consumer Health News Source Type: news

Godly gift for arthritis pain
Big Pharma is at it again… Creating and selling a drug that causes thousands of heart attacks and strokes each year. In 2015, the FDA asked drug makers to strengthen their warning labels. Since then, most have listed their dangerous side effects on the bottle. But one manufacturer thought they didn’t have to warn people about their dangerous drug. They marketed their product as a “unique” breakthrough. They even published studies promising it was “safe for long-term use.” 1 The drug is a 7-year-old arthritis drug called Actemra. It’s made by the Swiss pharmaceutical company Roche....
Source: Al Sears, MD Natural Remedies - October 5, 2017 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news

MRI Shows Bone Repair in Treated Spine Disease (CME/CE)
(MedPage Today) -- Structural lesions improved with etanercept in nonradiographic axial spondyloarthritis (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - October 2, 2017 Category: Primary Care Source Type: news

Sandoz ’s Erelzi available for multiple inflammatory disease treatment in Canada
Novartis division Sandoz has made its Erelzi (etanercept) therapy available for the treatment of multiple inflammatory diseases for patients in Canada. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 22, 2017 Category: Pharmaceuticals Source Type: news

Pfizer revenue misses on lower Prevnar, Enbrel sales
(Reuters) - Pfizer Inc reported quarterly revenue on Tuesday that missed Wall Street estimates, driven by lower demand for its rheumatoid arthritis treatment Enbrel and pneumonia vaccine Prevnar. (Source: Reuters: Health)
Source: Reuters: Health - August 1, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Pfizer quarterly revenue slips 2 percent
(Reuters) - Pfizer Inc reported a nearly 2 percent drop in quarterly revenue on Tuesday, driven by lower demand for its rheumatoid arthritis treatment Enbrel and pneumonia vaccine Prevnar. (Source: Reuters: Health)
Source: Reuters: Health - August 1, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Saving Vanessa, part 1: A mystery rash, a stroke and an epic rescue
Vanessa’s rash first appeared on her arms and legs when she 3 or 4 months old. It was red and bumpy and went away when she was sick with a virus, which happened often. Then it would come back. The dermatology team she saw at Boston Children’s Hospital was puzzled. “I was expecting they were going to think it was nothing, but they took it very seriously,” says Katherine Bell, one of Vanessa’s mothers. “They took a biopsy and very quickly realized they had no idea what it was.” Vanessa’s case was even featured at a regional dermatology conference where doctors take up mystery p...
Source: Thrive, Children's Hospital Boston - July 25, 2017 Category: Pediatrics Authors: Nancy Fliesler Tags: Diseases & Conditions Our Patients’ Stories Dr. Carolyn Rogers Dr. Pui Lee Dr. Robert Sundel Dr. Scellig Stone Dr. Todd Lyons stroke Source Type: news

Novartis unit Alcon posts modest Q2 gain
(Reuters) — Long-suffering Novartis (NYSE:NVS) unit Alcon‘s sales growth accelerated in the second quarter, boosting options for the business including a possible disposal, CEO Joe Jimenez said today. The eye care subsidiary’s sales rose 1% to $1.5 billion, including intraocular lens revenues, which grew for the first time in the second quarter since 2014. Spending continued to promote products with eye surgeons, resulting in a $19 million operating loss. Novartis has been reviewing Alcon for a possible disposal, with an update slated for this year. All options are under consideration, Jimenez reiter...
Source: Mass Device - July 18, 2017 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Mergers & Acquisitions Optical/Ophthalmic Wall Street Beat Alcon Novartis Source Type: news

Novartis gets European OK for biosimilar of Amgen's Enbrel
ZURICH (Reuters) - Novartis's generics unit Sandoz said the European Commission approved Erelzi, its biosimilar to Amgen's Enbrel, to treat inflammatory diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis. (Source: Reuters: Health)
Source: Reuters: Health - June 27, 2017 Category: Consumer Health News Tags: healthNews Source Type: news